Home › Kanser sa Baga › Missouri › Kansas City
Pag-aaral pangklinika para sa Kanser sa Baga sa Kansas City, MO
19 pag-aaral para sa Kanser sa Baga ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Kansas City (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Saint Luke's Hospital of Kansas City, Kansas City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Nagre-recruitPhase 3
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Nagre-recruitPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Kansas City Veterans Affairs Medical Center, Kansas City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Nagre-recruitPhase 3
- University Health Truman Medical Center, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Nagre-recruitPhase 1
- St. Lukes Hospital of Kansas City, Kansas City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Nagre-recruitPhase 3
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Nagre-recruitPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Nagre-recruitPhase 1/2
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi ang layo
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Nagre-recruitPhase 3
- The University of Kansas Cancer Center - Westwood, Westwood · 5 mi ang layo
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Nagre-recruitPhase 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood · 5 mi ang layo
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- University of Kansas Cancer Center - North, Kansas City
Integrated Cancer Repository for Cancer Research
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- at 1 pa
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Nagre-recruitPhase 1/2
- The University of Kansas Cancer Center, Westwood · 5 mi ang layo
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- at 1 pa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2/3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- at 2 pa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Nagre-recruitPhase 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- at 1 pa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Kansas City
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Nagre-recruitObservasyonal na pag-aaral
- Saint Lukes Hospital, Kansas City
Pag-aaral para sa Kanser sa Baga sa ibang lungsod
- Houston, TX78 pag-aaral
- Boston, MA62 pag-aaral
- New York City, NY60 pag-aaral
- Los Angeles, CA45 pag-aaral
- Arlington, VA41 pag-aaral
- Washington, DC41 pag-aaral
- Chicago, IL41 pag-aaral
- Nashville, TN40 pag-aaral
- Baltimore, MD40 pag-aaral
- St. Louis, MO39 pag-aaral
- Columbus, OH37 pag-aaral
- Philadelphia, PA36 pag-aaral
Iba pang pag-aaral sa Kansas City
- Kanser sa Suso34 pag-aaral
- Non-Small Cell Lung Cancer31 pag-aaral
- Pagkabigo ng Puso25 pag-aaral
- Kanser (lahat ng uri)21 pag-aaral
- Colorectal Cancer16 pag-aaral
- Metastatic Cancer15 pag-aaral
- Acute Myeloid Leukemia15 pag-aaral
- Kanser sa Prostate14 pag-aaral
- Kanser sa Ovary11 pag-aaral
- Obesity11 pag-aaral
- Type 2 Diabetes11 pag-aaral
- Sakit sa Puso at Ugat ng Dugo11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.